HA-irinotecan / Upstryve - LARVOL DELTA

Trial of FOLF(HA)Iri versus FOLFIRI in mCRC (FOLF(HA)iri) (clinicaltrials.gov) - P3, N=390; Sponsor: Alchemia Oncology; Recruiting -> Active, not recruiting; Completion date: NA -> Dec 2015

Enrollment closed • Colorectal Cancer

Alchemia announces half-year results for period ended 31 December 2013 (MENAFN news) - "Alchemia continued to treat patients in the company's pivotal phase III clinical trial of HA-Irinotecan in metastatic colorectal cancer (mCRC). The primary objective of the phase III study is to demonstrate that HA-Irinotecan is superior to Irinotecan in its effect on Progression Free Survival (PFS). The primary endpoint of this trial will be reached when 350 patients have experienced disease progression or death..."

Clinical protocol • Colorectal Cancer